Trastuzumab (T) plus vinorelbine (VNR) as first combination in Her-2 overexpressing patients with metastatic breast cancer.

被引:0
|
作者
Glogowska, I [1 ]
Sienkiewicz-Kozlowska, R [1 ]
Bauer-Kosinska, B [1 ]
Jaczewska, S [1 ]
Pienkowski, T [1 ]
机构
[1] Mem Marie Sklodowska Curie Canc Ctr, Warsaw, Poland
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
3165
引用
收藏
页码:235S / 235S
页数:1
相关论文
共 50 条
  • [1] EXPANDED EXPERIENCE WITH INTRAVENOUS OR ORAL VINORELBINE (VNR) PLUS TRASTUZUMAB (T) IN CHEMONAIVE PATIENTS WITH HER-2 OVEREXPRESSING METASTATIC BREAST CANCER (MBC)
    Bernardo, A.
    Palumbo, R.
    Villani, G.
    Strada, M. R.
    Bernardo, G.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
  • [3] Phase II Study of Vinorelbine Plus Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines and Taxanes
    Kwon, H.
    Oh, S. Y.
    Kim, S. H.
    Lee, S.
    Lee, J. H.
    Kim, H. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S353 - S353
  • [4] Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer
    Morabito, Alessandro
    Longo, Raffaele
    Gattuso, Domenico
    Carillio, Guido
    Massaccesi, Cristian
    Mariani, Luigi
    Bonginelli, Paola
    Amici, Scolastica
    De Sio, Livia
    Fanelli, Massimo
    Torino, Francesco
    Bonsignori, Maurizio
    Gasparini, Giampietro
    [J]. ONCOLOGY REPORTS, 2006, 16 (02) : 393 - 398
  • [5] Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer
    Bergen, Elisabeth
    Berghoff, Anna S.
    Rudas, Margaretha
    Dubsky, Peter
    De Vries, Catharina
    Sattlberger, Claudia
    Mader, Robert M.
    Zagouri, Flora
    Sparber, Cornelia
    Fitzal, Florian
    Gnant, Michael
    Rottenfusser, Andrea
    Zielinski, Christoph C.
    Preusser, Matthias
    Steger, Guenther G.
    Bartsch, Rupert
    [J]. BREAST CARE, 2014, 9 (05) : 344 - 348
  • [6] Vinorelbine and trastuzumab enhance effector cell function in patients with HER-2/neu overexpressing metastatic breast cancer
    Schwartz, GN
    Kaufman, PA
    Tretter, CPG
    Arrick, BA
    Mulrooney, TJ
    Connelly, EM
    Mellinger, DL
    Fisher, JL
    Ernsloff, MS
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S128
  • [7] Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
    Burstein, Harold J.
    Keshaviah, Aparna
    Baron, Ari D.
    Hart, Ronald D.
    Lambert-Falls, Rosemary
    Marcom, P. Kelly
    Gelman, Rebecca
    Winer, Eric P.
    [J]. CANCER, 2007, 110 (05) : 965 - 972
  • [8] Is the combination of trastuzumab and vinorelbine an active regimen in metastatic breast cancer patients overexpressing HER2/neu?
    Czerniawska, M
    Jagiello-Gruszfeld, AI
    Zbrzezniak, J
    Wachula, E
    Kazarnowicz, A
    Sikorska, M
    Szablowska-Siwik, S
    Ziomek, M
    Gugala, K
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 277 - 277
  • [9] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [10] Gemcitabine, vinorelbine and trastuzumab combination (GemVinT) as second-third line therapy for HER-2 overexpressing metastatic breast cancer (MBC).
    Morabito, A
    Carillio, G
    Bonginelli, P
    Amici, S
    Longo, R
    Sarmiento, R
    Fanelli, M
    Stani, SC
    Gattuso, D
    Gasparini, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 66S - 66S